Genomic Vision Announces the Issuance of the 3rd Tranche of Convertible Notes With Warrants (OCABSA) for €2 Million, as Part of the Financing Line Concluded With Winance for a Maximum Amount of €30 Million

Regulatory News:

Genomic Vision (FR0011799907 – GV, – the “Company”) (Paris:GV), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announces the issuance of the third tranche of convertible notes with equity warrants attached (OCABSA) for a total net amount of €1.92 million.

In a press release dated May 20, 2022, the Company announced the signing of a contract with Winance on April 11, 2022 as modified on May 18, 2022 to setting up a financing line by issuing convertible bonds (the “OC”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSA” and with the OC the “OCABSA”), for a maximum total amount of €28.8 million (€30 million nominal value). The extraordinary shareholders meeting of the Company held on May 23, 2022 approved the implementation of this financing line.

Terms of the operation

By using the delegation granted by the extraordinary shareholders meeting on May 23, 2022, Genomic Vision’s Executive Board decided, on June 23, 2023, to issue 2,000,000 convertible bonds with warrants (OCABSA) with a nominal value of €2 million for the benefit of Winance (the “Investor”) for a total net amount of €1.92 million, as well as 525,000 bonds convertible into shares delivered in payment of the second quarter of the Investor's commitment fee. The OCABSA were paid up in several installments, the last part of which was paid on June 23, 2023.

The gross proceeds of the transaction will therefore be €2 million and the net proceeds €1.92 million.

The main terms of this financing program structured in 15 tranches of OCABSA totaling €28.8 million are described in the prospectus approved by the Autorité des Marchés Financiers (AMF) on May 20, 2022 under no. 22-170, consisting of the universal registration document filed on April 14, 2022 under number D.22-0293, the amendment to the universal registration document filed on May 20, 2022 under number D.22-0293-A01, a transaction note and a summary, available at the Company's registered office (80-84 Rue des Meuniers, 92220 Bagneux), on the Company's website (www.genomicvision.com) and on that of the AMF (www.amf-france.org).